Lipid paradox in rheumatoid arthritis: Changes with rheumatoid arthritis therapies

Current Rheumatology Reports

Volumn 14, Issue 5, 2012, Pages 428-437

  Urruela, Matxalen Amezaga ^a   Suarez Almazor, Maria E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of General Internal Medicine and Ambulatory Treatment   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk; Lipid profile; Lipids; Markers of inflammation; Paradox; Rheumatoid arthritis; Risk factors; Therapy

Indexed keywords

ABATACEPT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TOCILIZUMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATHEROSCLEROSIS; BIOLOGICAL THERAPY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; JOINTS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; RISK FACTORS; SURVIVAL RATE;

EID: 84869153058     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0269-z     Document Type: Review

References (76)

1. John H, Toms TE, Kitas G. Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol. 2011; 26: 327-33.
2. Watson DJ, Rhodes T, Gues HA. All cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003; 30: 1196-202. (Pubitemid 36666340)
3. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischemic stroke in patients with rheumatoid arthritis in the Apolipoprotein- related Mortality RISK (AMORIS) Study. Ann Rheum Dis. 2010; 69: 1996-2001.
4. Del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional risks factors. Arthritis Rheum. 2001; 44: 2737-45. (Pubitemid 34016192)
5. Myasoedova E, Kremers HM, Fits-Gibbon P, et al. Lipid profile improves with the onset of rheumatoid arthritis. Ann Rheum Dis. 2009; 68 Suppl 3.
6. Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 1310-4.
7. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999; 26: 1701-4. (Pubitemid 29367308)
8. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987; 257: 2176-80. (Pubitemid 17055840)
9. Choy E, Sattar N. Interpreting lipid level in the context of high grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009; 68: 460-569. Th is article explains the relationship between inflammation and lipid profiles, why lipoproteins are altered in patients with RA, and how these changes can translate into clinical relevant CV risk factors.
10. Hahn BH, Grossman J, Chen WC, et al. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007; 28: 69-75. (Pubitemid 46670686)
11. Hahn BH, Grosmman J, Benjamin JA, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory highdensity lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2008; 10: 213.
12. Dahlen GH. Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994; 108: 111-26.
13. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: Effect of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol. 2004; 31: 1746-53.
14. Toms T, Symmons D, Kitas G. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010; 8: 301-26.
15. Dursunoglu D, Evrengul H, Polat B, et al. Lp (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int. 2005; 25: 241-5. (Pubitemid 40767825)
16. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991; 50: 366-8.
17. Peters MJL, Voskuyl AE, Sattar BA, et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract. 2010; 64: 1440-3.
18. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 52: 722-32. (Pubitemid 40365093)
19. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011; 70: 482-7. In this study, concrete evidence of the paradoxical relationship between lower levels of TC and LDLc and increased CV risk in patients with RA is demonstrated, as well as the interplay between inflammation as a CV risk factor.
20. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 958-61. (Pubitemid 46999801)
21. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2009; 38: 372-81.
22. Schimmel EK, Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol. 2009; 27: 446-51.
23. Park YB, Choi SJ, Kim MY, et al. Effects of anti-rheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med. 2002; 113: 188-93.
24. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med. 1994; 70: 863-70.
25. Bruce IN. "Not only.. but also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44: 1492-502. (Pubitemid 41742464)
26. Hafstrom I, Rohani M, Deneberg S, et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with Rheumatoid arthritis: a randomized study. J Rheumatol. 2007; 34: 1810-6. (Pubitemid 350067638)
27. Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDLcholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest. 2008; 38: 686-92.
28. Toms T, Panoulas V, Douglas K, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? Angiology. 2011; 62: 167-75. This study provides evidence on how, in the setting of inflammation, lipid ratios are less susceptible to changes induced by most antirheumatic drugs. Using these biomarkers as a more reliable method to evaluate lipid abnormalities can assist clinicians in their estimates of CV risk in patients with RA and in the management of traditional risk factors.
29. Rho YH, Oeser A, Chung C, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Info. 2009; 2: 34-40.
30. Chung C, Petri M, Post W, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the Multi-Ethnic Study of atherosclerosis. Semin Arthritis Rheum. 2012; 41: 535-44. This paper stresses the importance of controlling traditional CV risk factors in patients with RA. It shows that patients with RA have high rates of undiagnosed diabetes mellitus type 2, hypertension, and elevated LDLc and that fewer than 60% of them are able to achieve preestablished target goals for each of these conditions.
31. Ravindran V, Rachapalli S, Choy EH. Safety of medium to long term glucocorticoid therapy in rheumatoid arthritis: a metaanalysis. Rheumatology (Oxford). 2009; 48: 807-11.
32. Loddenkemper K, Bohl N, Perka C, et al. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. Rheumatol Int. 2006; 26: 331-6. (Pubitemid 43097528)
33. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008; 47: 72-5. (Pubitemid 350286266)
34. Hoes JN, Jacobs JW, Hulsmans HM, et al. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use: extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol. 2010; 28: 354-9.
35. Davis 3rd JM, Maradit-Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population- based cohort study. Arthritis Rheum. 2007; 56: 820-30. (Pubitemid 46399429)
36. Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997; 56: 374-7. (Pubitemid 27305426)
37. Morris SJ, Wasko MC. Antohe Jl, et al. Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis. Arthritis Care Res. 2011; 63: 530-4.
38. Cotroneo J, Sleik KM, Rene Rodriguez E, et al. Hydroxychloroquineinduced restrictive cardiomyopathy. Eur J Echocardiogr. 2007; 8: 247-51.
39. Naqvi TZ, Luthringer D, Marchevsky A, et al. Chloroquine induced cardiomyopathy-echocardiographic features. J Am Soc Echocardiogr. 2005; 18: 383-7.
40. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extra-high levels in VLDL triglyceride in patients with rheumatoid arthritis. J Rheumatol. 2007; 34: 1997-2004. (Pubitemid 47548201)
41. Westlake S, Colebatch A, Baird J, et al. The effects of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010; 48: 295-307.
42. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthrtisis Rheum. 2006; 55: 531-6. (Pubitemid 44289870)
43. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther. 2008; 117: 244-79.
44. Nam JL, Winthrop KL, Van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010; 69: 976-86.
45. Pollono EN, Lopez-Olivo MA, Lopez JA, et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol. 2010; 29: 947-55.
46. Van Sijl AM, Peters MJ, Knol DL, et al. The effect on TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a metaanalysis. Semin Arthritis Rheum. 2011; 41: 393-400.
47. Daien CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with metaanalysis. Ann Rheum Dis. 2012. doi: 10.1136/annrheumdis-2011-201148.
48. Gasparyan AY, Ayvazyan L, Cocco G, et al. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012; 18: 1543-55.
49. Barnabe C, Martin BJ, Ghali WA. Systematic review and metanalysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011; 63: 522-9.
50. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: rheumatological dilemma. Autoimmun Rev. 2005; 4: 153-61. (Pubitemid 40488744)
51. Solomon GE. T-cell agents in the treatment of rheumatoid arthritis. Bull NYU Jt Dis. 2010; 68: 162-5.
52. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009; 59: 1821-4.
53. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008; 59: 1821-4.
54. Novikova D, Popkova T, Nasonov E. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Curr Pharm Des. 2012; 18: 1512-8.
55. Gurcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009; 9: 10-25.
56. van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010; 37: 558-67.
57. Papanicolau DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin 6 in human disease. Ann Intern Med. 1998; 128: 127-37. (Pubitemid 28053135)
58. Gonzalez-Gay MA, Gonzalez-Juateney C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57: 125-32.
59. Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all cause mortality in chronic immune mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford). 2009; 48: 78-82.
60. Oldfield V, Dhillon S, Plosket GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009; 69: 609-32.
61. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; 7: CD008331.
62. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long term extensions. Md Rheumatol. 2010; 20: 222-32.
63. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the antiinterleukin- 6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011; 31: 451-6.
64. Bisoendial RJ, Stroes ES, Kastelein JJ, et al. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol. 2010; 6: 157-64.
65. Vishal T, Bano G, Khajuria V, et al. Pleitropic effects os statins. Ind J Pharmacol. 2003; 37: 77-85.
66. Semb AG, Holme I, Kvien TK, et al. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford). 2011; 50: 324-9.
67. De Vera MA, Choi H, Abrahamowicz M, et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2011; 70: 1020-4.
68. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010; 69: 683-8.
69. El-Barbary A, Hussein M, Rageh E, et al. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol. 2011; 38: 229-35.
70. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet. 2004; 363: 2015-21. (Pubitemid 38781100)
71. Jick SS, Choi H, Li L, et al. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 546-51.
72. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008; 5: e64.
73. Arts EE, Jansen TL, Den Broeder A, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREM) registry. Ann Rheum Dis. 2011; 70: 877-8.
74. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69: 325-31.
75. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of 10 year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987-1003. (Pubitemid 36712275)
76. Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2006; 8: R186.